Therapeutic potential of DCB-SLE1, an extract of a mixture of Chinese medicinal herbs, for severe lupus nephritis

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 4, 2011, Pages

  Tsai, Pei Yi ^a,b   Ka, Shuk Man ^a   Chang, Jia Ming ^b   Chang, Wen Liang ^a   Huang, Yuan Jen ^b   Hung, Le Mei ^b   Jheng, Huei Lin ^b   Wu, Rey Yuh ^b   Chen, Ann ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Hematuria; IL 17; IL 18; Natural killer cell; Proteinuria

Indexed keywords

AUTOANTIBODY; CHINESE DRUG; DCB SLE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATRACTYLODIS MACROCEPHALAE; B LYMPHOCYTE ACTIVATION; CELL ACTIVITY; CELL PROLIFERATION; CELLULAR IMMUNITY; CHINESE MEDICINE; CONTROLLED STUDY; EUCOMMIAE CORTEX; FEMALE; HEDYOTIDIS DIFFUSAE; HEMATURIA; HERB; IMMUNOMODULATION; INFLAMMATION; KIDNEY CELL; KIDNEY DYSFUNCTION; KIDNEY INJURY; LONICERAE CAULIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOID CELL; MACROPHAGE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEPHRITIS; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SALMONELLA; SPLEEN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UREMIA;

EID: 80053366058     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00706.2010     Document Type: Article

References (69)

1. Akhtar S, Li X, Kovacs EJ, Gamelli RL, Choudhry MA. Interleukin-18 delays neutrophil apoptosis following alcohol intoxication and burn injury. Mol Med 17: 88-94, 2011.
2. Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev 127: 25-50, 1992.
3. Bagavant H, Deshmukh US, Wang H, Ly T, Fu SM. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol 177: 8258-8265, 2006.
4. Bagavant H, Fu SM. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 21: 489-494, 2009.
5. Behara VY, Whittier WL, Korbet SM, Schwartz MM, Martens M, Lewis EJ. Pathogenetic features of severe segmental lupus nephritis. Nephrol Dial Transplant 25: 153-159, 2010.
6. Benseler SM, Bargman JM, Feldman BM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology (Oxford) 48: 176-182, 2009.
7. Chang JM, Huang KL, Yuan TT, Lai YK, Hung LM. The anti-hepatitis B virus activity of Boehmeria nivea extract in HBV-viremia SCID mice. Evid Based Complement Alternat Med 7: 189-195, 2008.
8. Chang JT, Segal BM, Nakanishi K, Okamura H, Shevach EM. The costimulatory effect of IL-18 on the induction of antigen-specific IFNgamma production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor beta2 subunit. Eur J Immunol 30: 1113-1119, 2000.
9. Costantini C, Micheletti A, Calzetti F, Perbellini O, Pizzolo G, Cassatella MA. Neutrophil activation and survival are modulated by interaction with NK cells. Int Immunol 22: 827-838, 2010.
10. Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16: 47-57, 2010.
11. Crispin JC, Tsokos GC. IL-17 in systemic lupus erythematosus. J Biomed Biotechnol 2010: 943254, 2010.
12. Cunningham MA, Huang XR, Dowling JP, Tipping PG, Holdsworth SR. Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis. J Am Soc Nephrol 10: 499-506, 1999.
13. Deocharan B, Qing X, Lichauco J, Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 168: 3072-3078, 2002.
14. Dong G, Ye R, Shi W, Liu S, Wang T, Yang X, Yang N, Yu X. IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl) 116: 543-548, 2003.
15. Esfandiari E, McInnes IB, Lindop G, Huang FP, Field M, Komai-Koma M, Wei X, Liew FY. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol 167: 5338-5347, 2001.
16. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 43: 197-208, 2004.
17. Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol 27: 47-58, 2007.
18. Gautam R, Jachak SM. Recent developments in anti-inflammatory natural products. Med Res Rev 29: 767-820, 2009.
19. Giner-Larza EM, Manez S, Recio MC, Giner RM, Prieto JM, Cerda-Nicolas M, Rios JL. Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity. Eur J Pharmacol 428: 137-143, 2001.
20. Goto M, Tanimoto K, Horiuchi Y. Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum 23: 1274-1281, 1980.
21. Ha H, Ho J, Shin S, Kim H, Koo S, Kim IH, Kim C. Effects of Eucommiae Cortex on osteoblast-like cell proliferation and osteoclast inhibition. Arch Pharm Res 26: 929-936, 2003.
22. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 107: 9813-9818, 2010.
23. He Z, Lu L, Altmann C, Hoke TS, Ljubanovic D, Jani A, Dinarello CA, Faubel S, Edelstein CL. Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. Am J Physiol Renal Physiol 295: F1414-F1421, 2008.
24. Hill GS, Delahousse M, Nochy D, Bariety J. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 68: 2288-2297, 2005.
25. Hoffman T. Natural killer function in systemic lupus erythematosus. Arthritis Rheum 23: 30-35, 1980.
26. Hu S, Cai W, Ye J, Qian Z, Sun Z. Influence of medicinal herbs on phagocytosis by bovine neutrophils. Zentralbl Veterinarmed A 39: 593-599, 1992.
27. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman WA, Tervaert JW, Jennette JC, Heeringa P. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 167: 47-58, 2005.
28. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248-257, 2001.
29. Ka SM, Cheng CW, Shui HA, Wu WM, Chang DM, Lin YC, Chen A. Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res Ther 9: R67, 2007.
30. Ka SM, Kuo YC, Ho PJ, Tsai PY, Hsu YJ, Tsai WJ, Lin YL, Shen CC, Chen A. (S)-armepavine from Chinese medicine improves experimental autoimmune crescentic glomerulonephritis. Rheumatology (Oxford) 49: 1840-1851, 2010.
31. Ka SM, Rifai A, Chen JH, Cheng CW, Shui HA, Lee HS, Lin YF, Hsu LF, Chen A. Glomerular crescent-related biomarkers in a murine model of chronic graft versus host disease. Nephrol Dial Transplant 21: 288-298, 2006.
32. Ka SM, Sytwu HK, Chang DM, Hsieh SL, Tsai PY, Chen A. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. J Am Soc Nephrol 18: 2473-2485, 2007.
33. Kim KA, Lee JS, Park HJ, Kim JW, Kim CJ, Shim IS, Kim NJ, Han SM, Lim S. Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes. Life Sci 74: 2769-2779, 2004.
34. Kojo S, Sada KE, Kobayashi M, Maruyama M, Maeshima Y, Sugiyama H, Makino H. Clinical usefulness of a prognostic score in histological analysis of renal biopsy in patients with lupus nephritis. J Rheumatol 36: 2218-2223, 2009.
35. Kuo YC, Yang NS, Chou CJ, Lin LC, Tsai WJ. Regulation of cell proliferation, gene expression, production of cytokines, and cell cycle progression in primary human T lymphocytes by piperlactam S isolated from Piper kadsura. Mol Pharmacol 58: 1057-1066, 2000.
36. Kyttaris VC, Tsokos GC. T lymphocytes in systemic lupus erythematosus: an update. Curr Opin Rheumatol 16: 548-552, 2004.
37. Li R, Sakwiwatkul K, Yutao L, Hu S. Enhancement of the immune responses to vaccination against foot-and-mouth disease in mice by oral administration of an extract made from Rhizoma atractylodis macrocephalae (RAM). Vaccine 27: 2094-2098, 2009.
38. Liu CC, Navratil JS, Sabatine JM, Ahearn JM. Apoptosis, complement and systemic lupus erythematosus: a mechanistic view. Curr Dir Autoimmun 7: 49-86, 2004.
39. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5: 1260-1265, 2004.
40. Mok MY, Wu HJ, Lo Y, Lau CS. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 37: 2046-2052, 2010.
41. Molino C, Fabbian F, Longhini C. Clinical approach to lupus nephritis: recent advances. Eur J Intern Med 20: 447-453, 2009.
42. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 19: 557-574, 2010.
43. Postol E, Meyer A, Cardillo F, de Alencar R, Pessina D, Nihei J, Mariano M, Mengel J. Long-term administration of IgG2a anti-NK1.1 monoclonal antibody ameliorates lupus-like disease in NZB/W mice in spite of an early worsening induced by an IgG2a-dependent BAFF/BLyS production. Immunology 125: 184-196, 2008.
44. Roussel L, Houle F, Chan C, Yao Y, Berube J, Olivenstein R, Martin JG, Huot J, Hamid Q, Ferri L, Rousseau S. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 184: 4531-4537, 2010.
45. Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Karre K, Berg L. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126: 140-146, 2009.
46. Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 180: 1938-1947, 2008.
47. Schwartz MM, Korbet SM, Katz RS, Lewis EJ. Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis. Lupus 18: 149-158, 2009.
48. Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 23: 1298-1306, 2008.
49. Seery JP, Cattell V, Watt FM. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(beta-o-methyl)- fluoromethylketone. J Immunol 167: 2452-2455, 2001.
50. Seredkina N, Zykova SN, Rekvig OP. Progression of murine lupus nephritis is linked to acquired renal Dnase1 deficiency and not to upregulated apoptosis. Am J Pathol 175: 97-106, 2009.
51. Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J, Kang I. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 12: R53, 2010.
52. Shahrara S, Pickens SR, Mandelin AM, 2nd, Karpus WJ, Huang Q, Kolls JK, Pope RM. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 184: 4479-4487, 2010.
53. Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG. Natural killer cells determine the outcome of B cellmediated autoimmunity. Nat Immunol 1: 245-251, 2000.
54. Shui HA, Ka SM, Wu WM, Lin YF, Hou YC, Su LC, Chen A. LPS-evoked IL-18 expression in mesangial cells plays a role in accelerating lupus nephritis. Rheumatology (Oxford) 46: 1277-1284, 2007.
55. Subbaramaiah K, Michaluart P, Sporn MB, Dannenberg AJ. Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res 60: 2399-2404, 2000.
56. Summers SA, Steinmetz OM, Li M, Kausman JY, Semple T, Edgtton KL, Borza DB, Braley H, Holdsworth SR, Kitching AR. Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol 20: 2518-2524, 2009.
57. Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45: 1732-1740, 1966.
58. Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol 17: 1253-1263, 2006.
59. Tucci M, Ciavarella S, Strippoli S, Dammacco F, Silvestris F. Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells: a review. Ann NY Acad Sci 1173: 449-457, 2009.
60. Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 154: 247-254, 2008.
61. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 58: 251-262, 2008.
62. Tucci M, Stucci S, Strippoli S, Silvestris F. Cytokine overproduction, T-cell activation, and defective T-regulatory functions promote nephritis in systemic lupus erythematosus. J Biomed Biotechnol 2010: 457146, 2010.
63. Turner JE, Paust HJ, Steinmetz OM, Peters A, Riedel JH, Erhardt A, Wegscheid C, Velden J, Fehr S, Mittrucker HW, Tiegs G, Stahl RA, Panzer U. CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis. J Am Soc Nephrol 21: 974-985, 2010.
64. Uhm WS, Na K, Song GW, Jung SS, Lee T, Park MH, Yoo DH. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 42: 935-938, 2003.
65. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15: 241-250, 2004.
66. Xu H, Xu HE. Analysis of trace elements in Chinese therapeutic foods and herbs. Am J Chin Med 37: 625-638, 2009.
67. Yang N, Nikolic-Paterson DJ, Ng YY, Mu W, Metz C, Bacher M, Meinhardt A, Bucala R, Atkins RC, Lan HY. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 4: 413-424, 1998.
68. Yap DY, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010: 365083, 2010.
69. Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH, Venalis A, Adu D, Smolen JS, Emery P. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 63: 525-529, 2004.